Skin Cancer Unit, Nantes University Hospital, INSERM, Nantes, France.
Acta Derm Venereol. 2011 Sep;91(5):562-7. doi: 10.2340/00015555-1113.
The aim of this retrospective study was to assess the efficacy and tolerance of intravenous rituximab in multifocal primary cutaneous follicle centre lymphomas (PCFCL). Eleven patients with a multifocal PCFCL were treated with rituximab (MabThera(®)) administrated intravenously. After four infusions, an objective response was observed in 90% of patients, and one month after all the infusions (median of 6 infusions) all the patients had an objective response and complete remission was obtained in 7 of 11 patients (64%). Follow-up ranged from 9 to 65 months (median: 30 months). Local disease recurrence was observed in five patients. The median progression-free survival time after the end of treatment was 23.6 months. This study is the largest series of patients with multifocal primary PCFCL treated with intravenous rituximab. This therapy is a safe and effective treatment and could represent an excellent alternative treatment to radiotherapy.
本回顾性研究旨在评估静脉用利妥昔单抗治疗多灶性原发性皮肤滤泡中心淋巴瘤（PCFCL）的疗效和耐受性。11 例多灶性 PCFCL 患者接受利妥昔单抗（美罗华®）静脉给药治疗。在进行了 4 次输注后，90%的患者观察到客观缓解，在所有输注结束后 1 个月（中位数为 6 次输注），所有患者均观察到客观缓解，11 例患者中有 7 例（64%）获得完全缓解。随访时间为 9 至 65 个月（中位数：30 个月）。5 例患者出现局部疾病复发。治疗结束后无进展生存时间的中位数为 23.6 个月。本研究是接受静脉用利妥昔单抗治疗的最大系列多灶性原发性 PCFCL 患者。该治疗方法安全有效，可能是放疗的理想替代治疗方法。
